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DObjective: Early invasive strategy, defined as early coronary angiography and subsequent revascularization,
when appropriate, is recommended by current guidelines for the management of patients with moderate- to
high-risk acute coronary syndromes. We sought to compare the outcomes of patients with acute coronary
syndromes undergoing surgical revascularization with an on-pump versus off-pump approach.
Methods: Among a total of 13,819 patients with moderate- to high-risk acute coronary syndromes enrolled in
the Acute Catheterization and Urgent Intervention Triage Strategy trial, 1375 patients were triaged to isolated
coronary artery bypass grafting. One thousand one hundred fifty-four patients underwent operations with
cardiopulmonary bypass (the coronary artery bypass grafting group), and 221 patients underwent off-pump
coronary artery bypass grafting (the off-pump coronary artery bypass grafting group). Propensity score match-
ing (1:3) was applied to adjust for differences in baseline clinical and angiographic characteristics, yielding
a total of 880 matched patients with acute coronary syndromes (220 managed with off-pump coronary artery
bypass grafting and 660 managed with coronary artery bypass grafting).
Results:At 30 days, patients undergoing off-pump coronary artery bypass grafting had fewer events of bleeding
(43.7% vs 56.3%, P ¼ .0005) and myocardial infarction (7.3% vs 12.1%, P ¼ .055) but higher rates of rein-
tervention (3.7% vs 1.2%,P¼ .02). At 1 year, therewas no difference between groups in death, total myocardial
infarctions, reinterventions, strokes, or major adverse cardiac events, but there was a lower rate of non–Q-wave
myocardial infarctions in the off-pump coronary artery bypass grafting group (4.6% vs 9.2%, P ¼ .03).
Conclusions: In this large-scale study evaluating the outcomes of patients with acute coronary syndromes, off-
pump coronary artery bypass grafting was associated with lower rates of bleeding and non–Q-wave myocardial
infarction but more reinterventions early after the procedure. At 1 year, there was no major outcome difference
between the 2 surgical strategies. (J Thorac Cardiovasc Surg 2011;142:e33-9)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Caonary syndromes (ACSs)1 and is the recommended approach
of the American Heart Association, the American College of
Cardiology, and the European Society of Cardiology.2,3 The
traditional surgical approach of cooling the patient by
postponing the surgical procedure in high-risk ACS scenarios
to allowstabilizationbefore theoperationhasbeenchallenged
by recent reports validating thepositive role of coronaryartery
bypass grafting (CABG) in patients with ACSs.4-6
Although admission to hospitalswith anACS (ie, unstable
angina and non–ST-segment elevationmyocardial infarction
[MI]) is a common and highly frequent occurrence, there are
limited data illuminating the superior surgical strategy for
these high-risk patients. Of interest are recent reports claim-
ing that off-pump coronary artery bypass grafting (OPCAB)
might reduce ischemic injury to the myocardium7-11 and
suggesting some early benefit for the OPCAB technique
after EuroSCORE stratification of patients presenting with
active ischemia and unstable angina.12
In this reportwe conducted a subgroup analysis for the out-
come of patients with coronary disease who presented with
moderate- to high-risk ACSs enrolled in the large-scalerdiovascular Surgery c Volume 142, Number 2 e33
Abbreviations and Acronyms
ACS ¼ acute coronary syndrome
ACUITY ¼ Acute Catheterization and Urgent
Intervention Triage Strategy
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPK ¼ creatine phosphokinase
MACE ¼ major adverse cardiac event
MB ¼ myocardial band
MI ¼ myocardial infarction
OPCAB ¼ off-pump coronary artery bypass
grafting
OR ¼ odds ratio
ULN ¼ upper limit of normal
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Dcontemporary Acute Catheterization and Urgent Interven-
tion Triage Strategy (ACUITY) trial with subsequent
revascularization by means of either CABG or OPCAB.
MATERIALS AND METHODS
The ACUITY trial was a prospective, open-label, randomized, multi-
center trial that compared 3 different antithrombotic regimens for patients
presenting with moderate- or high-risk ACSs between August 2003 and
December 2005 and who were treated with an early invasive strategy.
The study design and protocol, as well as its principal results, have been
described previously in detail.13 In brief, 13,819 patients presenting with
non–ST-segment elevation ACSs were randomized to receive unfractio-
nated heparin or enoxaparin with a glycoprotein IIb/IIIa inhibitor, bivalir-
udin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. Per
protocol, angiographic analysis was intended in all patients within 72 hours
of randomization, with subsequent triage to percutaneous coronary inter-
vention, CABG surgery, or medical management.
Inclusion criteria for entering the study were age of 18 years or greater
with symptoms of unstable angina lasting 10 minutes or more within 24
hours, with 1 or more of the following criteria: new ST-segment depression
or transient elevation of 1mmor greater; increased troponin I, troponin T, or
creatine kinase–myocardial band (MB) levels; known coronary artery dis-
ease; or all 4 other Thrombolysis in Myocardial Infarction risk criteria.14,15
Exclusion criteria included acute ST-segment elevation MI or shock,
bleeding diathesis or major bleeding within 2 weeks, thrombocytopenia,
creatinine clearance of 30 mL/min or less, or recent administration of ab-
ciximab, warfarin, fondaparinux, fibrinolytic agents, bivalirudin, or more
than 1 dose of low-molecular-weight heparin. The study was approved
by institutional review boards or ethics committees at each center, and
all patients provided written informed consent.
All patients undergoing CABG received unfractionated heparin as the
anticoagulant, with dosing per standard institutional practice. For patients
initially randomized to bivalirudin or enoxaparin, the drugwas discontinued
for at least 1 or 8 hours (if possible) before surgical intervention (for biva-
lirudin and enoxaparin, respectively). Finally, a 5-day clopidogrel washout
period was recommended for patients who received clopidogrel before
angiographic analysis and in whom CABG was subsequently planned.
End Points and Definitions
Prespecified end points were assessed at 30 days and 1 year after the pro-
cedure and included death, MI, composite ischemia, unplanned revascular-
ization for ischemia, and combinations of the above defined as compositee34 The Journal of Thoracic and Cardiovascular Surgischemia (major adverse cardiac events [MACEs]) and were adjudicated by
a blinded clinical events committee.
In all patients undergoingCABG, diagnosis of perioperativeMI required
the following: (1) any creatine phosphokinase (CPK)–MB level of 103 or
greater of the upper limit of normal (ULN) or CPK of 103 or greater of the
ULN in the absence of MB determination within 24 hours of CABG and in-
creased at least 50% over themost recent pre-CABG levels or (2) anyCPK–
MB level of 53 or greater of the ULN (or CPK 53 of the ULN in the
absence of MB determination) within 24 hours of CABG and increased at
least 50% over themost recent pre-CABG levels alongwith new significant
(0.04 s) Q-waves in 2 or more contiguous electrocardiographic leads.
The somewhat strict ACUITY scale definitions for a bleeding event
were as follows: reoperation for bleeding, reduction in hemoglobin concen-
tration of 3 g/dL or greater with an overt source of bleeding (or 4 g/dL
without), use of any blood product transfusion, and intracranial or intraoc-
ular bleeding.
Statistical Analysis
Continuous variables are summarized as means  standard deviations
and compared by using 2-sample t tests. Categorical variables are summa-
rized with frequencies and percentages and compared by using c2 or
Fisher’s exact tests, where appropriate. Multivariable logistic regression
was used to evaluate risk factors for death, MACEs, MI, and reintervention.
Odds ratios (ORs) and 95% confidence intervals (CIs) are given. Event
curves for postoperative survival, MACEs, MI, and reintervention are gen-
erated by using the Kaplan–Meier method, and comparison between
groups is made with the log-rank test. To eliminate all differences between
the groups, we further performed a propensity score analysis that was
matched for sex, weight, hypertension, ST-segment deviation of 1 mm or
greater, and the number of diseased vessels. The probability (propensity
score) that a patient would undergo CABG or OPCAB according to the pre-
procedural variables was determined by using a saturated logistic regres-
sion model to take into account the different patient profiles. Each
patient from the OPCAB group was then matched with 3 patients from
the CABG group according to their propensity scores, resulting in 880
propensity-matched patients (220 in the OPCAB group and 660 in the
CABG group) in whom early and late outcomes were determined.
Categorical variables were compared by using c2 or Fisher’s exact tests.
Continuous variables were compared by using the nonparametricWilcoxon
rank sum test. Time-to-event data are displayed by using Kaplan–Meier
methodology and were compared with the log-rank test. All analyses
were performed with SAS software (SAS Institute, Inc, Cary, NC).
Finally, allocation to treatment group for the present study was made on
the basis of the intention to treat. Patients converted during the procedure
from the off-pump technique to CABG with cardiopulmonary bypass were
thus included in the OPCAB group.RESULTS
Among a total of 13,819 patients with moderate- to high-
risk ACSs in the ACUITY trial, a total of 1375 (9.9%) were
triaged to isolated CABG. Among these, there were 231 pa-
tients who underwent initial operations without the use of
cardiopulmonary bypass (the OPCAB group) and 1154
who underwent operations with cardiopulmonary bypass
(the CABG group). There was no difference in initial ran-
domization to antithrombotic regimen between the groups,
and the initial antithrombotic regimen was included in the
multivariable analysis model. There was also no difference
between time from study drug cessation to the surgical
procedure. All study antiaggregants were discontinued in
a timely manner before surgical intervention (Table 1).ery c August 2011
TABLE 1. Randomization for different antithrombotic regimens (n ¼ 880)
Antithrombotic regimen Off pump On pump P value
Randomized to heparinþ IIb/IIIa 35.0% (77/220) 35.8% (236/660) .8710
Randomized to bivalirudinþ IIb/IIIa 35.0% (77/220) 30.6% (202/660) .2417
Randomized to bivalirudin alone 30.0% (66/220) 33.6% (222/660) .3615
Time from any study drug stop to CABG (h) 64.04  82.59 88.22  363.32 .1338
Time from heparin stop to CABG (h) 43.89  65.41 157.12  898.45 .2468
Time from bivalirudin stop to CABG (h) 64.86  83.85 75.64  122.48 .2570
Time from bivalirudinþIIb/IIIA stop to CABG (h) 89.91  92.47 85.03  104.24 .7320
CABG, Coronary artery bypass grafting.
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Patients in the CABG group had more extensive coronary
disease, with 2.59  0.7 diseased vessels versus 2.44  0.8
diseased vessels in the OPCAB group (P ¼ .007); were
more likely to present with ST-segment deviation of more
than 1 mm (51.1% vs 43.0%, P ¼ .03); and had a slightly
higher body weight (85.1  17.6 vs 82.7  15.9 kg,
P ¼ .04). The complete baseline clinical and angiographic
characteristics of the patients are displayed in Table 2.
At 1 month, there was no difference between groups in
mortality (3.6% vs 3.2%, OPCAB vs CABG; P ¼ .76), MI
(7.3% vs 11.4, OPCAB vs CABG; P ¼ .07), stroke (0.0%TABLE 2. Baseline clinical and angiographic characteristics of the study c
Off pump (n ¼ 22
Age at randomization (y) 64.66  10.59 (22
Male sex 80.5% (178/221)
Weight (kg) 82.70  15.98 (22
Diabetes 31.4% (69/220)
Insulin diabetes 11.8% (26/220)
Hypertension 71.0% (157/221)
Hyperlipidemia 54.1% (118/218)
Current smoker 28.3% (62/219)
Previous MI 24.8% (53/214)
Previous PTCA 22.7% (50/220)
Previous CABG 3.6% (8/221)
Renal insufficiency 22.9% (47/205)
Baseline cardiac biomarker increase 73.6% (153/208)
Baseline troponin increase 68.3% (136/199)
ST-segment deviation 1 mm 43.0% (95/221)
Baseline cardiac biomarker increase or
ST-segment deviation
84.4% (178/211)
TIMI risk score
Low (0–2) 11.3% (23/203)
Intermediate (3–4) 51.2% (104/203)
High (5–7) 37.4% (76/203)
No. of diseased vessels 2.44  0.77 (221
LAD disease 91.0% (201/221)
LCX disease 77.8% (172/221)
RCA disease 75.6% (167/221)
LM disease 31.7% (70/221)
Multivessel disease 85.5% (189/221)
Left ventricular ejection fraction (%) 54.01  12.95 (16
MI, Myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CAB
LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary art
The Journal of Thoracic and Cavs 1.0%, OPCAB vs CABG; P ¼ .23), acute renal injury
(28.2% vs 31.5%, OPCAB vs CABG; P ¼ .39), or MACEs
(11.3% vs 14.1%, OPCAB vs CABG; P¼ .28). Patients un-
dergoingOPCABhad a lower rate of non–Q-waveMI (3.2%
vs 8.0%,P¼ .01) and a lower rate of bleeding events (43.6%
vs 54.3%, P ¼ .001) but required more unplanned coronary
reinterventions (3.6% vs 1.0%, P ¼ .001).
Late Outcome
At 1 year (up to 395 days), there was no difference
between the groups in total or cardiac-related mortality,
MI, stroke, unplanned reintervention, or MACEs (Table 3).ohort (n ¼ 1375)
1) On pump (n ¼ 1154) P value
1) 64.12  10.17 (1154) .47
76.3% (881/1154) .19
1) 85.06  17.64 (1152) .04
34.7% (398/1146) .35
11.1% (127/1146) .72
65.6% (756/1153) .12
50.7% (567/1118) .37
27.7% (315/1136) .87
24.1% (274/1135) .86
21.3% (243/1143) .65
4.5% (52/1153) .72
17.2% (186/1082) .06
73.9% (797/1079) .93
71.4% (740/1037) .39
51.1% (590/1154) .03
86.5% (959/1109) .45
11.5% (119/1034) 1.00
55.2% (571/1034) .31
33.3% (344/1034) .25
) 2.59  0.69 (1154) .007
93.0% (1073/1154) .32
82.8% (955/1154) .08
83.5% (964/1154) .006
31.2% (360/1154) .87
91.1% (1051/1154) .013
5) 51.86  13.44 (906) .06
G, coronary artery bypass grafting; TIMI, Thrombolysis in Myocardial Infarction;
ery; LM, left main artery.
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TABLE 3. Early and late clinical outcomes (n ¼ 1375)
Off pump
(n ¼ 221)
On pump
(n ¼ 1154)
P
value
1-mo Outcomes (to 35 d)
Major adverse cardiac events 11.3% (25) 14.1% (162) .28
Death/MI 10.0% (22) 13.6% (157) .14
Death 3.6% (8) 3.2% (37) .76
Cardiac death 3.6% (8) 3.0% (35) .65
Noncardiac death 0.0% (0) 0.1% (1) .66
MI 7.3% (16) 11.4% (131) .07
Q-wave MI 4.1% (9) 3.6% (41) .71
Non–Q-wave MI 3.2% (7) 8.0% (91) .01
Unplanned revascularization 3.6% (8) 1.0% (11) .002
PCI 2.3% (5) 0.7% (8) .03
CABG 1.4% (3) 0.3% (3) .02
CVA 0.0% (0) 1.0% (11) .23
TIA 0.0% (0) 0.3 (3) 1.00
Acute renal injury* 28.2% (53) 31.5% (323) .39
Bleeding eventsy 43.6% (96) 54.3% (624) .001
Reoperation for bleeding 0.9% (2) 1.1% (13) .77
Blood product transfusion 35.4% (78) 41.4%(475) .07
1-y Outcomes (to 395 d)
Major adverse cardiac events 17.8% (39) 18.4% (211) .76
Death/MI 15.1% (33) 15.9% (182) .69
Death 6.9% (15) 5.3% (60) .35
Cardiac death 4.1% (9) 3.8% (44) .85
Noncardiac death 2.9% (6) 1.3% (14) .08
MI 9.2% (20) 11.8% (135) .24
Q-wave MI 4.1% (9) 3.7% (42) .75
Non–Q-wave MI 5.1% (11) 8.4% (96) .08
Unplanned revascularization 6.1% (13) 3.8% (42) .11
PCI 4.7% (10) 3.5% (38) .35
CABG 1.4% (3) 0.4% (5) .09
CVA 0.0% (0) 1.0% (12) .23
TIA 0.0% (0) 0.3 (3) 1.00
Rates are displayed as Kaplan–Meier percentage estimates (number of events). MI,
Myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary
artery bypass grafting;CVA, cerebrovascular accident; TIA, transient ischemic attack.
*Denotes a relative 25% increase or absolute 0.5 mg/dL increase in serum creatinine
values after the procedure compared with baseline values. yAcute Catheterization and
Urgent Intervention Triage Strategy (ACUITY) scale definition for bleeding: reoper-
ation for bleeding, reduction in hemoglobin concentration of 3 g/dL or greater with an
overt source of bleeding (or 4 g/dL without), use of any blood product transfusion,
and intracranial/intraocular bleeding.
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year mortality were not significantly different according
to revascularization strategy (OR ¼ 0.89 [95% CI, 0.3–
2.67], P ¼ .98, and OR ¼ 1.57 [95% CI, 0.74–3.32],
P ¼ .24, for OPCAB vs CABG at 1 month and 1 year, re-
spectively). However, OPCABwas associated with a signif-
icant increase in the rate of early unplanned reinterventions
(OR¼ 4.1 [95% CI, 1.59–10.6], P¼ .003) and a lower rate
of bleeding events (OR ¼ 0.6 [95% CI, 0.46–0.84],
P ¼ .002).
Of note, 36 patients initially triaged forOPCABeventually
underwent operations with cardiopulmonary bypass. The ex-
act cause of that alteration for each patient was unobtainable,
and further study showed that although there were no preop-
erative differences between patients undergoing ‘‘standard’’
CABG and those who were converted to CABG (apart
from the small difference of a higher percentage ofmale sub-
jects in the converted group: 91.7% vs 76.3%, P ¼ .028),
these patients had higher rates of unplanned reinterventions
both early (8.3% vs 1.0%, P<.0001) and late (11.2% vs
3.8%, P ¼ .02) after the procedure compared with patients
initially selected for standard CABG strategy. This verifies
the notion that improper strategy selection with concomitant
conversion fromanoff-pump to anon-pumpprocedurehas its
price.
Results After Propensity Score Matching
As described in the statistical analysis section, propensity
score matching (1:3) was applied to adjust for differences
between groups, yielding a total of 880 matched patients
with ACSs (220 managed with OPCAB and 660 managed
with CABG). The baseline clinical and angiographic char-
acteristics of the 2 propensity-matched groups were bal-
anced in all measured characteristics apart from a 6.3%
difference in the extent of right coronary artery disease
(Table 4). In the OPCAB group the mean number of grafts
per patient was 2.8  1.2, whereas in the CABG group
patients had a mean of 3.4  1.03 grafts per patient
(P<.0001). Exact operative data, such as the type of graft
and exact number of vessels treated in the CABG group,
could not be generated accurately from the ACUITY data-
base configuration. The mean duration of hospitalization
was 13.0  10.9 days for the OPCAB group versus 13.0 
17 days for the CABG group (P<.94). There was also no
difference in time from procedure to discharge between
the groups (8.9  10.2 vs 8.7  6.8 days, OPCAB vs
CABG; P ¼ .79).
At 1 month, there was no difference in all-cause mortal-
ity (3.7% vs 3.6%, OPCAB vs CABG; P ¼ .99), cardiac
mortality, MACEs, stroke rate, and acute renal injury in
patients managed with OPCAB versus CABG. The rates
of MI and bleeding events were higher in the CABG group
(12.1% vs 7.3%, P ¼ .055, and 56.3% vs 43.7%,
P ¼ .0005, CABG vs OPCAB); however, the rate ofe36 The Journal of Thoracic and Cardiovascular Surgunplanned repeat revascularization for ischemia was
higher in the OPCAB group (1.2% vs 3.7%, P ¼ .02).
At 1 year, there was no difference in all propensity-
adjusted outcomes between the groups apart from non–
Q-wave MI rates that were higher in the CABG group
(9.2% vs 4.6%, P ¼ .03). The outcomes of the multivari-
able analysis and propensity score analysis are provided in
Table 5 and Figure 1.DISCUSSION
An aggressive approach of early angiographic analysis
with subsequent revascularization (by means of eitherery c August 2011
TABLE 4. Baseline clinical and angiographic characteristics after propensity matching (1:3), (n ¼ 880)
Off pump (n ¼ 220) On pump (n ¼ 660) P value
Age at randomization (y) 64.63  10.61 (220) 64.90  10.30 (660) .74
Male sex 80.5% (177/220) 82.1% (542/660) .61
Weight (kg) 82.72  16.02 (220) 83.47  15.41 (660) .54
Diabetes 31.5% (69/219) 34.7% (228/657) .41
Insulin diabetes 11.9% (26/219) 10.2% (67/657) .52
Hypertension 70.9% (156/220) 72.0% (475/660) .795
Hyperlipidemia 53.9% (117/217) 52.9% (338/639) .81
Current smoker 28.4% (62/218) 27.2% (177/650) .72
Previous MI 24.9% (53/213) 25.3% (164/647) .93
Previous PTCA 22.8% (50/219) 22.4% (146/652) .92
Previous CABG 3.6% (8/220) 4.9% (32/659) .57
Renal insufficiency 23.0% (47/204) 18.8% (118/629) .19
Baseline cardiac biomarker increase 73.4% (152/207) 73.9% (457/618) .92
Baseline troponin increase 68.3% (136/199) 71.3% (424/595) .47
ST-segment deviation 1 mm 42.7% (94/220) 43.3% (286/660) .94
Baseline cardiac biomarker increase or ST-segment deviation 84.3% (177/210) 84.9% (533/628) .82
TIMI risk score
Low (0–2) 11.4% (23/202) 10.2% (60/589) .69
Intermediate (3–4) 51.5% (104/202) 54.3% (320/589) .51
High (5–7) 37.1% (75/202) 35.5% (209/589) .67
No. of diseased vessels 2.44  0.77 (220) 2.52  0.75 (660) .15
LAD disease 90.9% (200/220) 90.8% (599/660) 1.0000
LCX disease 77.7% (171/220) 79.8% (527/660) .50
RCA disease 75.5% (166/220) 81.8% (540/660) .05
LM disease 31.8% (70/220) 32.6% (215/660) .87
Multivessel disease 85.5% (188/220) 88.6% (585/660) .23
Left ventricular ejection fraction (%) 54.01  12.95 (165) 51.79  13.78 (675) .07
See abbreviations in Table 2.
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DCABG or percutaneous coronary intervention), when ap-
propriate, has been shown to be the superior approach for
patients presenting with moderate- to high-risk ACSs16
and is recommended by current US and European guide-
lines for treating these patients.2,3 From the surgical
perspective, the traditional convention of cooling off the
patient by postponing the procedure during active
ischemia has been challenged by a few recent studies.
One, a retrospective analysis describing the outcomes of
12,988 unselected patients with ACSs, demonstrated that
early CABG (performed in 267 of the patients) was an
independent predictor of lower mortality (OR, 0.12).4
This report, as well as other communications describing
the safety and efficacy of surgical revascularization during
ACSs, has reinforced the role of CABG in this setting.5,6
Experience with OPCAB has increased dramatically
since the late 1990s, and it has been shown by numerous au-
thors to be safe, reproducible, and effective for patients with
coronary artery disease,17,18 including those considered to
be at high operative risk for various reasons.19,20
Although many studies have attempted to identify the
potential advantages of off-pump techniques over tradi-
tional approaches, most have been undersized or underpow-
ered to detect differences in relevant outcome measures,The Journal of Thoracic and Casuch as survival, MI, reintervention, or adverse neurologic
events.
A recent prospective randomized trial comparing both
techniques in a sizeable cohort of 2203 patients (mostly in
nonurgent settings) found no difference in 30-day or 1-year
mortality between patients undergoing OPCAB and those
undergoingCABG,with a lower rate of the 1-year composite
outcome of mortality, MI, and reintervention in the CABG
group. This was accompanied by a superior graft patency
rate in the CABGgroup among the 1371 patients who under-
went follow-up coronary angiographic analysis (82.6% vs
87.8%, OPCAB vs CABG; P< .01).21 These results are
consistent with a previous, smaller prospective randomized
trial evaluating outcomes after off-pump procedures.9
In the subpopulation of actively ischemic patients, some
speculate that off-pump CABG might reduce the extent of
myocardial damage, perhaps through avoidance of ischemic
arrest and reperfusion injury, earlier revascularization of the
culprit lesion, attenuation of the no-reflow phenomenon,
and reduction of myocardial edema.8-11 A recent report by
Rastan and colleagues7 demonstrated that beating-heart
techniques implemented during active ischemia reduced
in-hospital adverse outcome measures, such as transfusion
requirements, extensive inotropic support, prolongedrdiovascular Surgery c Volume 142, Number 2 e37
TABLE 5. Early and late clinical outcomes for the propensity-
matched cohort (n ¼ 880)
Off pump
(n ¼ 220)
On pump
(n ¼ 660)
P
value
1-mo Outcomes (to 35 d)
Major adverse cardiac events 11.4% (25) 15.5% (102) .13
Death/MI 10.0% (22) 14.7% (97) .08
Death 3.7% (8) 3.6% (24) .99
Cardiac death 3.7% (8) 3.3% (22) .83
Noncardiac death 0.0% (0) 0.2% (1) .56
MI 7.3% (16) 12.1% (79) .055
Q-wave MI 4.1% (9) 3.1% (20) .44
Non–Q-wave MI 3.2% (7) 9.0% (59) .005
Unplanned revascularization 3.7% (8) 1.2% (8) .02
PCI 2.3% (5) 0.8% (5) .07
CABG 1.4% (3) 0.5% (3) .16
Acute renal injury* 28.3% (53/187) 33.3% (198/594) .21
Bleeding eventsy 43.7% (96) 56.3% (371) .0005
Reoperation for bleeding 0.9% (2) 0.9 (6) 1.0
Blood product transfusion 35.6%(78) 42.3 (279) .58
CVA 0.0% (0) 1.1% (7) .20
TIA 0.0% (0) 0.3% (2) 1.0
1-y outcomes (to 395 d)
Major adverse cardiac events 17.4% (38) 18.2% (120) .69
Death/MI 14.7% (32) 16.2% (107) .50
Death 6.9% (15) 5.2% (34) .36
Cardiac death 4.1% (9) 4.3% (28) .92
Noncardiac death 2.9% (6) 0.8% (5) .02
MI 8.7% (19) 12.2% (80) .15
Q-wave MI 4.1% (9) 3.1% (20) .44
Non–Q-wave MI 4.6% (10) 9.2% (60) .03
Unplanned revascularization 5.6% (12) 3.2% (20) .09
PCI 4.2% (9) 2.7% (17) .25
CABG 1.4% (3) 0.5% (3) .16
CVA 0.0% (0/220) 1.1% (7/660) .20
TIA 0.0% (0/220) 0.3% (2/660) 1.0
Rates are displayed as Kaplan–Meier percentage estimates (number of events). See
abbreviations in Table 3. *Denotes a relative 25% increase or absolute 0.5 mg/dL
increase in serum creatinine values after the procedure compared with baseline
values. yAcute Catheterization and Urgent Intervention Triage Strategy (ACUITY)
scale definition for bleeding: reoperation for bleeding, reduction in hemoglobin
concentration of 3 g/dL or greater with an overt source of bleeding (or 4 g/dL
without), use of any blood product transfusion, and intracranial/intraocular bleeding.
FIGURE 1. One-year outcomes (in percentages) for patients undergoing
off-pump coronary artery bypass grafting (OPCAB) and coronary artery
bypass grafting (CABG).MI, Myocardial infarction;MACE, major adverse
cardiac events; CVA, cerebrovascular accident.
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Dventilation time, intensive care unit stay, and in-hospital
stroke rate. A report by Biancari and associates12 evaluated
314 patients with unstable angina, of whom half underwent
operations without the use of cardiopulmonary bypass, and
found no difference in early or intermediate mortality
between the 2 groups (1.9% vs 3.9%, OPCAB vs CABG;
P ¼ .33) or in postoperative stroke rate, renal dysfunction,
or MACEs. The only difference detected between groups
was a lower transfusion requirement in the OPCAB group.
Of note, after stratifying patients by their EuroSCORE
level, the authors found an apparent early survival and early
MACE benefit for those undergoing operations without
cardiopulmonary bypass.
In this report we describe the early and midterm clinical
outcomes of 1375 patients presenting with moderate- toe38 The Journal of Thoracic and Cardiovascular Surghigh-risk ACSs who underwent surgical myocardial revascu-
larization with or without cardiopulmonary bypass in the
large-scale, contemporaryACUITY trial. Themajor outcome
difference between matched groups was in the early postop-
erative period, with patients undergoing OPCAB having
lower bleeding events and MI rates and a higher incidence
of unplanned coronary reinterventions, whereas at 1 year, pa-
tients undergoing OPCAB had a lower rate of non–Q-wave
MIs. In multivariable analysis OPCAB revascularization
again was associated with more unplanned early reinterven-
tions. These results are consistent with previous studies
performed in various patient populations.8-10,22-24 The lower
perioperative MI rate might be explained by the minimization
of myocardial injury attendant to the avoidance of ischemic
arrest,7-10,22 whereas the higher reintervention rate might be
related either to the more technically demanding nature of
performing coronary anastomoses on the beating heart, to the
greater tendency to perform incomplete revascularization with
this approach, or both.7,25
Our study has its limitations, including the fact that
patients in the ACUITY trial were randomized to different
initial antithrombotic regimens at presentation but not to
the surgical approach. Selection of the exact surgical tech-
nique and of the revascularization strategy in general was
left to the judgment of the clinical investigators and is
thus subject to the limitations of selection bias. In addition,
because the ACUITY trial was not a surgical trial, some co-
variates, such as vessel diameter, angiographic appearance,
completeness of revascularization, the exact type of graft
used or vessels treated, and the surgeon’s level of experi-
ence, could not be included in the analysis. Finally, the
follow-up period of 1 year might not suffice for true
evaluation of either surgical strategy.
In conclusion, in this analysis of patients presenting with
moderate- to high-risk ACSs and treated with early surgical
revascularization, OPCAB was associated with reducedery c August 2011
Ben-Gal et al Acquired Cardiovascular Diseasemyocardial injury and bleeding, along with more reinter-
ventions early after the procedure. We believe that although
these findings are representative of the actual tradeoffs asso-
ciated with these 2 surgical approaches, they reaffirm the
safety and legitimacy of both modalities in these high-risk
patients.A
C
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